Eubiologics. 

Established in 2010 and based in Seoul, South Korea, EuBiologics Co., Ltd. is a biopharmaceutical company dedicated to developing and supplying essential vaccines for epidemics and antibiotic resistance within the country. Its product portfolio includes Euvchol, an oral vaccine for cholera prevention, and CRM197, a diphtheria toxin-mutant vaccine. Beyond its vaccine offerings, the company provides comprehensive, customized services for biopharmaceuticals derived from mammalian and microbial cells, guiding clients through various project stages such as cell line development, GMP production, validation, and regulatory assistance. EuBiologics operates advanced facilities equipped for the manufacturing of protein-based therapeutics and antibodies, with a particular specialization in recombinant biological products and antibody treatments. Additionally, the company offers expertise in process, formulation, and analytical method development, provides licensing consulting, and delivers a range of contract testing services, including lot release, stability, raw material, and method validation.